The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant cells exhibited moderate cytoplasmic staining. A few cases of ovarian, endometrial, breast, pancreatic and colorectal cancers showed strong cytoplasmic positivity. Malignant gliomas, most malignant lymphomas and renal cancers along with several testicular cancers were weakly stained or negative.
Most malignant cells exhibited moderate cytoplasmic positivity. A few lung, renal and liver cancers were strongly stained. Most cases of malignant gliomas, testicular and prostate cancers along with several malignant lymphomas, cervical and skin cancers were weakly stained or negative.
Validation
Two (or more) antibodies yielding similar or partly similar staining patterns and there is no available gene/protein characterization data
Two (or more) antibodies yielding similar or partly similar staining patterns and there is no available gene/protein characterization data
